Stock Rating Upgrade
Reflecting improving fundamentals and high Appreciation Potential, the Value Trend Rating for Regeneron Pharmaceuticals Inc (NASDAQ: REGN) improved in recent days. REGN’s current Value Trend Rating is C and the prior Rating was D. Details supporting this higher rating are included in our next report.
Recent Price Action
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) stock rose slightly by 0.2% on 3/28/25. The stock closed at $637.36. However, trading volume in this advance was unusually low at 57% of normal. The stock has been extremely weak relative to the market over the last nine months and has declined -3.8% during the last week.
Current PriceTarget Research Rating
Regeneron Pharmaceuticals has a current Value Trend Rating of C (Low Neutral). This VT Rating improved in recent days from D previously. The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Regeneron Pharmaceuticals has a good Appreciation Score of 84 but a very low Power Rating of 2, leading to the Low Neutral Value Trend Rating.
Be the first to comment